Karo Bio Announces Successful Phase II Study With Eprotirome In Combination With Statin
Aug 11th 2008Drug InformationCholesterol
Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein (a) and was safe and well tolerated.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
